Mocan Z, Erem C, Yildirim M, Telatar M, Değer O
Department of Internal Medicine, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey.
Diabetes Res. 1994;26(3):101-7.
To assess whether urinary N-acetyl-beta-D-glucosaminidase (NAG) and beta 2-microglobulin (beta 2-MG) levels could be used as predictors of diabetic nephropathy or not, 59 non-insulin-dependent diabetes mellitus (NIDDM) patients were included in our study (31 females, 29 males; mean age 54 +/- 10.1). The control group consisted of 20 healthy non-diabetic subjects (12 males and 8 females; mean age 47 +/- 13.9). The patients in the study group were classified according to the duration of diabetes. In all cases, urinary beta 2-MG levels were measured by specific enzyme immunoassays and urinary NAG enzyme activities were determined by colorimetric methods. The mean urinary NAG level in study group was higher than that of the control group (p < 0.01). It was observed that NAG activity begins to rise in the third year of NIDDM, makes a plateau between 3-10 years, and rapidly increases after the 10th year. No significant difference in NAG activity was found between chemical NIDDM and control groups. No significant difference in beta 2-MG levels was found between study and control groups. The mean NAG activity in patients with early glomerular hyperfiltration was significantly higher than those without early hyperfiltration and control group (p < 0.05), whereas the mean beta 2-MG level was not. As a result, urinary NAG enzyme activity significantly increases, while urinary beta 2-MG level remains unchanged in patients with NIDDM. It was concluded that measurement of urinary NAG enzyme activity may be a good indicator in early diagnosis of diabetic nephropathy.
为了评估尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)和β2-微球蛋白(β2-MG)水平是否可作为糖尿病肾病的预测指标,我们纳入了59例非胰岛素依赖型糖尿病(NIDDM)患者(31例女性,29例男性;平均年龄54±10.1岁)进行研究。对照组由20名健康非糖尿病受试者组成(12例男性和8例女性;平均年龄47±13.9岁)。研究组患者根据糖尿病病程进行分类。所有病例中,尿β2-MG水平通过特异性酶免疫测定法测量,尿NAG酶活性通过比色法测定。研究组尿NAG平均水平高于对照组(p<0.01)。观察到NAG活性在NIDDM第三年开始升高,在3至10年之间趋于平稳,在第10年后迅速增加。化学性NIDDM组与对照组之间NAG活性无显著差异。研究组与对照组之间β2-MG水平无显著差异。早期肾小球高滤过患者的平均NAG活性显著高于无早期高滤过患者及对照组(p<0.05),而平均β2-MG水平则不然。结果,NIDDM患者尿NAG酶活性显著增加,而尿β2-MG水平保持不变。得出的结论是,测定尿NAG酶活性可能是糖尿病肾病早期诊断的一个良好指标。